Nr 5 recruiting BASIL
Row Saved Status Study Title Conditions Interventions Locations
1 Recruiting Patient Registry to Evaluate the Real-world Safety of Ruconest®
Hereditary Angioedema
Drug: rhC1INH
The US Hereditary Angioedema Association
Fairfax, Virginia, United States
2 Recruiting RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
Kidney Failure
Drug: rhC1INH
Other: Saline Solution
University of Wisconsin
Madison, Wisconsin, United States
3 Recruiting A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
CVI - Common Variable Immunodeficiency
Biological: C1-esterase inhibitor [recombinant] (C1-INH-R)
IMMUNOe Research Centers
Centennial, Colorado, United States
4 Completed Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Hereditary Angioedema
Drug: rhC1INH
Portland Clinical Research/AAIM Care, LLC
Portland, Oregon, United States
UIA FN Plzen ( Institute of Immunology and Allergology), Faculty Hospital Plzen
Plzen, Alej Svobody 80, Czechia
University Hospital Motol, Institute of Immunology
Prague, V Úvalu 84, Czechia
(and 13 more...)
[b]5 Recruiting Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Coronavirus Infections
Drug: Conestat alfa
[i]University Hospital Basel, Division of Internal Medicine
Basel, Switzerland[/b][/i]
6 Withdrawn Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Graft Rejection
Kidney Transplantation
Procedure: plasmapheresis and IVIG
Drug: recombinant C1 inhibitor
University of Wisconsin
Madison, Wisconsin, United States
7 Completed
Has Results A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Hereditary Angioedema
Biological: Recombinant human C1 inhibitor
Other: Placebo
University of South Florida Asthma, Allergy and Immunology Clinical Research Unit
Tampa, Florida, United States
University of South Florida, Asthma, Allergy & Immunology Clinical Research Unit
Tampa, Florida, United States
Washington University Division of Allergy and Immunology
Saint Louis, Missouri, United States
(and 7 more...)
8 Completed Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Genetic Disorders
Drug: i.v. recombinant human C1 inhibitor
For information on sites in Europe, please contact Pharming Technologies.
Leiden, Netherlands
9 Completed Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Genetic Disorders
Drug: i.v. recombinant human C1 inhibitor
For information contact Sonja Visscher
Leiden, Netherlands
10 Completed
Has Results Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary Angioedema
Angioneurotic Edema
Genetic Disorders
Drug: recombinant human C1 inhibitor
Drug: Placebo
For information on sites, please contact Pharming Medical Affairs Deparment
Leiden, Netherlands
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department
Tirgu Mures, Romania
Ruud..